Home » Cephalon Receives FDA Approval of REMS for GABITRIL
Cephalon Receives FDA Approval of REMS for GABITRIL
Cephalon, Inc. announced that a Risk Evaluation and Mitigation Strategy (REMS) for its antiepileptic medication GABITRIL (tiagabine hydrochloride) has been approved.
KansasCity
KansasCity
Upcoming Events
-
07May
-
14May
-
30May